hMSH2 and GTBP in Ovarian Cancer
Author Information
Author(s): Ercoli A, Ferrandina G, Raspaglio G, Marone M, Maggiano N, Mastro P Del, Panici P Benedetti, Mancuso S, Scambia G
Primary Institution: Departments of Gynecology and Pathology, Catholic University of the Sacred Heart, Rome, Italy
Hypothesis
The study investigates the expression levels of hMSH2 and GTBP proteins in advanced stage epithelial ovarian cancer and their significance.
Conclusion
The study found that hMSH2 expression is significantly lower in stage IV ovarian cancer patients and in non-responding patients to chemotherapy.
Supporting Evidence
- hMSH2 and GTBP proteins were detected in 95% of the samples analyzed.
- hMSH2 expression was significantly higher in ovarian cancer cells from solid tumors than from ascites.
- hMSH2 levels were significantly lower in stage IV patients compared to stage III patients.
- Non-responding patients had significantly lower hMSH2 levels compared to those who responded to chemotherapy.
Takeaway
This study looked at two proteins in ovarian cancer and found that one of them, hMSH2, is lower in more advanced cases and in patients who don't respond to treatment.
Methodology
Western blotting was used to analyze the expression levels of hMSH2 and GTBP proteins in untreated epithelial ovarian cancer samples.
Limitations
The study did not find significant differences in protein levels based on patient age, grade of differentiation, histotype, or extent of surgical debulking.
Participant Demographics
Patients with advanced stage epithelial ovarian cancer.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website